Powered by Oncomine™ from Thermo Fisher Scientific
Next-Gen Sequencing Breast Panel Based on the Technologies of Biocept and Thermo Fisher Scientific
Combining Biocept’s Liquid Biopsy biomarker testing expertise with Oncomine™ from Thermo Fisher Scientific’s next-generation sequencing and decision support resources.
- Exclusive, targeted and actionable
- Cost effective NGS-based solution
- Turn-around-time (7-10 days upon receipt of specimen in most cases)
- Sensitivity: 94.1-100% (MAF ≥0.1%)
- Raw data available for further research
- Specimen requirements: 8 mLs of peripheral blood in CEE-SURE™ or EDTA Tube
PD-L1, PR, ER, and AR expression testing available through Target Selector™ Circulating Tumor Cell (CTC) testing.
Current Gene List
All genes in pink font are referenced in NCCN Guidelines and/or are associated with FDA-approved therapy.